drugset / Trial / NCT00377559
Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open phase II multicentre study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®) and docetaxel (Taxotere®) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.
Timeline
- Start
- 2006-05
- Primary completion
- 2009-11
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |